Aclaris Therapeutics Inc.

17.71+0.6200+3.63%Vol 304.95K1Y Perf 649.36%
Sep 15th, 2021 16:00 DELAYED
BID17.66 ASK17.71
Open16.96 Previous Close17.09
Pre-Market- After-Market-
 - -%  - -
Target Price
34.80 
Analyst Rating
Strong Buy 1.40
Potential %
96.50 
Finscreener Ranking
★★★+     51.19
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★★★     55.95
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★     53.10
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
54.96 
Earnings Rating
Strong Buy
Market Cap1.08B 
Earnings Date
3rd Nov 2021
Alpha0.03 Standard Deviation0.37
Beta0.61 

Today's Price Range

16.9617.72

52W Range

2.2530.38

5 Year PE Ratio Range

-9.40-2.00

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
0.80%
1 Month
29.55%
3 Months
-1.56%
6 Months
-25.46%
1 Year
649.36%
3 Years
15.83%
5 Years
-27.71%
10 Years
-

TickerPriceChg.Chg.%
ACRS17.710.62003.63
AAPL149.030.91000.61
GOOG2 904.1236.00001.26
MSFT304.825.03001.68
XOM56.421.84003.37
WFC46.640.59001.28
JNJ165.420.62000.38
FB373.92-2.6100-0.69
GE102.161.78001.77
JPM158.161.09000.69
Financial StrengthValueIndustryS&P 500US Markets
15.60
16.20
0.04
0.05
-
Leverage Ratio 1.40
ProfitabilityValueIndustryS&P 500US Markets
16.10
-770.60
-760.30
-
-
RevenueValueIndustryS&P 500US Markets
6.63M
0.11
-6.75
-
Earnings HistoryEstimateReportedSurprise %
Q02 2021-0.26-0.34-30.77
Q01 2021-0.27-0.57-111.11
Q04 2020-0.28-0.31-10.71
Q03 2020-0.29-0.2513.79
Q02 2020-0.34-0.2817.65
Q01 2020-0.29-0.36-24.14
Q04 2019-0.34-0.46-35.29
Q03 2019-0.54-0.56-3.70
Earnings Per EndEstimateRevision %Trend
9/2021 QR-0.2715.63Positive
12/2021 QR-0.350.00-
12/2021 FY-1.540.65Positive
12/2022 FY-1.46-3.55Negative
Next Report Date3rd Nov 2021
Estimated EPS Next Report-0.27
Estimates Count5
EPS Growth Next 5 Years %-
Volume Overview
Volume304.95K
Shares Outstanding61.22M
Shares Float52.13M
Trades Count4.16K
Dollar Volume10.91M
Avg. Volume1.44M
Avg. Weekly Volume471.41K
Avg. Monthly Volume381.78K
Avg. Quarterly Volume566.75K

Aclaris Therapeutics Inc. (NASDAQ: ACRS) stock closed at 17.71 per share at the end of the most recent trading day (a 3.63% change compared to the prior day closing price) with a volume of 305.38K shares and market capitalization of 1.08B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 60 people. Aclaris Therapeutics Inc. CEO is Neal Walker.

The one-year performance of Aclaris Therapeutics Inc. stock is 649.36%, while year-to-date (YTD) performance is 173.72%. ACRS stock has a five-year performance of -27.71%. Its 52-week range is between 2.25 and 30.38, which gives ACRS stock a 52-week price range ratio of 54.96%

Aclaris Therapeutics Inc. currently has a PE ratio of -12.10, a price-to-book (PB) ratio of 4.62, a price-to-sale (PS) ratio of 164.26, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -37.46%, a ROC of -46.28% and a ROE of -49.49%. The company’s profit margin is -%, its EBITDA margin is -760.30%, and its revenue ttm is $6.63 Million , which makes it $0.11 revenue per share.

Of the last four earnings reports from Aclaris Therapeutics Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.27 for the next earnings report. Aclaris Therapeutics Inc.’s next earnings report date is 03rd Nov 2021.

The consensus rating of Wall Street analysts for Aclaris Therapeutics Inc. is Strong Buy (1.4), with a target price of $34.8, which is +96.50% compared to the current price. The earnings rating for Aclaris Therapeutics Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Aclaris Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Aclaris Therapeutics Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 30.32, ATR14 : 1.04, CCI20 : 69.86, Chaikin Money Flow : 0.09, MACD : 0.67, Money Flow Index : 79.58, ROC : 12.87, RSI : 62.36, STOCH (14,3) : 76.03, STOCH RSI : 0.55, UO : 48.44, Williams %R : -23.97), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Aclaris Therapeutics Inc. in the last 12-months were: Anand Mehra (Option Excercise at a value of $268 298), David N. Gordon (Option Excercise at a value of $0), David N. Gordon (Sold 2 631 shares of value $44 675 ), Frank Ruffo (Option Excercise at a value of $0), Frank Ruffo (Sold 87 339 shares of value $2 310 106 ), Kamil Ali-Jackson (Option Excercise at a value of $479 700), Kamil Ali-Jackson (Sold 45 000 shares of value $1 083 718 ), Neal Walker (Option Excercise at a value of $0), Neal Walker (Sold 30 000 shares of value $805 239 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (80.00 %)
4 (80.00 %)
4 (80.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (20.00 %)
1 (20.00 %)
1 (20.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.40
Strong Buy
1.40
Strong Buy
1.40

Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage specialty pharmaceutical company which operates in United States. It focuses on identifying, developing and commercializing differentiated drugs to address significant unmet needs in dermatology. The company holds a drug candidate, A-101 Topical Solution which is a proprietary high-concentration hydrogen peroxide topical solution which is being developed as a prescription treatment for seborrheic keratosis (SK) a common non-malignant skin tumor. Its pipeline of drug candidates includes A-101 as a Topical Solution for treatment of SK, common warts; A-102 as a gel dosage form for treatment of SK and warts and A-201 and A-301 as an oral and topical formulation for treatment of autoimmune dermatologic respectively.

CEO: Neal Walker

Telephone: +1 484 324-7933

Address: 640 Lee Road, Wayne 19087, PA, US

Number of employees: 60

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

67%33%

Bearish Bullish

56%44%

Bearish Bullish

57%43%

TipRanks News for ACRS

Mon, 09 Aug 2021 10:26 GMT Aclaris Therapeutics (ACRS) Gets a Buy Rating from H.C. Wainwright

- TipRanks. All rights reserved.

News

Stocktwits